An Open Label, Phase Ia/Ib Trial of the DNA-PK Inhibitor MSC2490484A in Combination With Radiotherapy in Patients With Advanced Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 03 Aug 2017
At a glance
- Drugs M 3814 (Primary) ; Cisplatin
- Indications Head and neck cancer; Non-small cell lung cancer; Solid tumours
- Focus Adverse reactions
- Sponsors EMD Serono
- 12 Jul 2017 Planned number of patients changed from 136 to 90.
- 12 Jul 2017 Planned End Date changed from 1 Jan 2021 to 7 Aug 2020.
- 12 Jul 2017 Planned primary completion date changed from 1 Jan 2021 to 7 Aug 2020.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History